Chemoradiotherapy for locally advanced head and neck cancer

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4118-4126

  Salama, Joseph K ^b   Seiwert, Tanguy Y ^b   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; GEFITINIB; HYDROXYUREA; METHOTREXATE; NIMORAZOLE; PACLITAXEL; TIRAPAZAMINE; TNFERADE; UFT; UNCLASSIFIED DRUG; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG FATALITY; DRUG INHIBITION; DRUG MEGADOSE; DYSPHAGIA; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LEUKOPENIA; LOADING DRUG DOSE; LUNG CANCER; META ANALYSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NECK DISSECTION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OROPHARYNX CANCER; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; ANIMAL; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 34748917052     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.2697     Document Type: Review

References (78)

1. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group - Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
2. Bourhis J: Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 24:489s, 2004 (suppl; abstr 5505)
3. Budach W, Hehr T, Budach V, et al: A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28, 2006
4. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16:1310-1317, 1998
5. Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23:6730-6738, 2005
6. Lee AW, Lau WH, Tung SY, et al: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23:6966-6975, 2005
7. Lin JC, Jan JS, Hsu CY, et al: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 21:631-637, 2003
8. Chan AT, Leung SF, Ngan RK, et al: Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97:536-539, 2005
9. Kwong DL, Sham JS, Au GK, et al: Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study. J Clin Oncol 22:2643-2653, 2004
10. Baujat B, Audry H, Bourhis J, et al: Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Oxford, United Kingdom, Cochrane Library, CD004329, 2006
11. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al: Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 36:999-1004, 1996
12. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
13. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
14. Cooper J, Pajak T, Forastiere A, et al: Long-term survival results of a phase III Intergroup trial (RTOG 95-01) of surgery followed by radiotherapy vs radiochemotherapy for resectable high risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 66:S14-15, 2006
15. Bernier J, Cooper JS, Pajak TF, et al: Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27:843-850, 2005
16. Fietkau R, Lautenschläger C, Sauer, et al: Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96-3. J Clin Oncol 24:5507, 2006
17. Seiwert TY, Salama JK, Vokes EE: The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4:86-100, 2007
18. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
19. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
20. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
21. Forastiere M, Weber RS, Pajak T, et al: Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx - Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol, 24:284s, 2006 (abstr 5517)
22. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
23. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
24. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998
25. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18:1458-1464, 2000
26. Staar S, Rudat V, Stuetzer H, et al: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161-1171, 2001
27. Seiwert TY, Salama JK, Vokes EE: The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 4:156-171, 2007
28. Machtay M: Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: An RTOG analysis. J Clin Oncol 24:280s, 2006 (suppl; abstr 5500)
29. Eisbruch A: Intensity-modulated radiation therapy in the treatment of head and neck cancer. Nat Clin Pract Oncol 2:34-39, 2005
30. Rosenthal DI, Lewin JS, Eisbruch A: Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24:2636-2643, 2006
31. Jeremic B, Shibamoto Y, Stanisavljevic B, et al: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol 43:29-37, 1997
32. Rasch C: Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer, early results of a multi-institutional trial. Persented at the 25th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, October 24-27, 2006, Leipzig, Germany
33. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
34. Haraf DJ, Rosen FR, Stenson K, et al: Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 9:5936-5943, 2003
35. Adelstein DJ, Saxton JP, Rybicki LA, et al: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. J Clin Oncol 24:1064-1071, 2006
36. Vokes EE, Stenson K, Rosen FR, et al: Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21:320-326, 2003
37. Vokes EE, Stenson KM, Kistner E, et al: Sequential evaluation of reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC). J Clin Oncol 24:287s, 2006 (suppl; abstr 5528)
38. Machtay M, Rosenthal DI, Hershock D, et al: Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: A University of Pennsylvania Phase II Trial. J Clin Oncol 20:3964-3971, 2002
39. Garden AS, Harris J, Vokes EE, et al: Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22:2856-2864, 2004
40. Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor donogen repopulation during radiotherapy. Acta Oncol 27:131-146, 1988
41. Nguyen LN, Ang KK: Radiotherapy for cancer of the head and neck: Altered fractionation regimens. Lancet Oncol 3:693-701, 2002
42. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy fpr head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
43. Bourhis J, Overgaard J, Audry H, et al: Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368:843-854, 2006
44. Overgaard J, Hansen HS, Specht L, et al: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933-940, 2003
45. Kam MK: Impact of intensity-modulated radiotherapy (IMRT) on salivary gland function in early stage nasopharyngeal carcinoma (NPC) patients. J Clin Oncol 23:500s, 2005 (abstr 5501)
46. Butler EB, Teh BS, Grant WH 3rd, et al: Smart (simultaneous modulated accelerated radiation therapy) boost: A new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 45:21-32, 1999
47. Lee NY, de Arruda FF, Puri DR, et al: A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:966-974, 2006
48. Graff P, Lapeyre M, Desandes E, et al: Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: Matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 67:1309-1317, 2007
49. Cohen EE, Haraf DJ, Stenson KM, et al: Integration of Gefitinib (G), into a Concurrent Chemoradiation (CRT) Regimen Followed by G Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer (HNC) - a Phase II Trial. J Clin Oncol 23:501s, 2005 (abstr 5506)
50. Pfister DG, Su YB, Kraus DH, et al: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24:1072-1078, 2006
51. Nordsmark M, Bentzen SM, Rudat V, et al: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study. Radiother Oncol 77:18-24, 2005
52. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
53. Rischin D, Peters L, Fisher R, et al: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87, 2005
54. Le QT, Taira A, Budenz S, et al: Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer 106:1940-1949, 2006
55. Seiwert TY, Haraf DJ, Cohen EE, et al: A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). J Clin Oncol 24:287s, 2006 (suppl; abstr 5530)
56. Zorat PL, Paccagnella A, Cavaniglia G, et al: Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96:1714-1717, 2004
57. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994
58. Domenge C, Hill C, Lefebvre JL, et al: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma: French Graupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83:1594-1598, 2000
59. Schuller DE, Metch B, Stein DW, et al: Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98:1205-1211, 1988
60. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial - EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996
61. Argiris A, Haraf DJ, Kies MS, et al: Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: Reversing a pattern of failure. Oncologist 8:350-360, 2003
62. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005
63. Posner M, Hershock D, Le-Lann L, et al: TAX 324: A phase III trial of TPF vs PF induction chemotherapy followed by chemoradiotherapy in locally advanced SCCHN. ASCO Special Session, 2006
64. Vermorken JB, Remenar E, C VH: Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC, #24971). J Clin Oncol 22:490s, 2004 (abstr 5508)
65. Remenar E, van Herpen J, Germa Lluch J, et al: A phase III multicenter trial of neoadjuvant docetaxel plus cisplatin plus 5-FU (TPF) in locally advanced unresectable squamous cell carcinoma of the head & neck: Final analysis of EORTC trial 24971. J Clin Oncol 24:284s, 2006 (abstr 5516)
66. Hitt R, Grau J, Lopez-Pousa A, et al: Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 24:283s, 2006 (suppl; abstr 5515)
67. Paccagnella A, Buffoli A, Koussis H, et al: Randomized phase II trial of concomitant CT/RT versus TPF followed by concomitant CT/RT in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 24:284s. 2006 (suppl; abstr 5518)
68. Urba S, Wolf G, Eisbruch A, et al: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 24:593-598, 2006
69. Haddad R, Tishler R, Wirth L, et al: Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 132:678-681, 2006
70. Stenson KM, Huo D, Blair E, et al: Planned post-chemoradiation neck dissection: Significance of radiation dose. Laryngoscope 116:33-36, 2006
71. Argiris A, Stenson KM, Brockstein BE, et al: Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 26:447-455, 2004
72. Strasser MD, Gleich LL, Miller MA, et al: Management implications of evaluating the N2 and N3 neck after organ preservation therapy. Laryngoscope 109:1776-1780, 1999
73. Liauw SL, Mancuso AA, Amdur RJ, et al: Postradiotherapy neck dissection for lymph node-positive head and neck cancer: The use of computed tomography to manage the neck. J Clin Oncol 24:1421-1427, 2006
74. Yao M, Graham MM, Hoffman HT, et al: The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 59:1001-1010, 2004
75. Rogers JW, Greven KM, McGuirt WF, et al: Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys 58:694-697, 2004
76. Brizel DM, Prosnitz RG, Hunter S, et al: Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 58:1418-1423, 2004
77. Knab BR, Salama JK, Stenson KM, et al: Definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 66:S14, 2006
78. Adelstein DJ, Leblanc M: Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 24:2624-2628, 2006